The Trump administration’s orders have created more turmoil and damage at the National Institutes of Health than was previously known.
A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback